Search the Newsreel

Vivani Medical: Q2 Earnings Snapshot

Invivyd (IVVD) widens loss, warns on going concern as cash falls to $160M

Invivyd, Inc. (IVVD) reported a widened net loss of $85.8 million for the first half of 2026 and warned of substantial doubt about its ability to continue as a going concern, as its cash and cash equivalents fell to $160.1 million. The company's PEMGARDA …

Invivyd, Inc. Q2 2026: Revenue $14.29M, EPS $(0.14) — 10-Q Summary

Invivyd, Inc. reported its second-quarter 2026 results, showing a 21.2% year-over-year revenue increase to $14.29 million, driven by demand for PEMGARDA. Despite this, the company experienced a widened net loss of $(44.39) million, resulting in a diluted loss per share of $(0.14). Significant progress …

Vivani Medical (VANI) widens GLP‑1 pipeline, funds runway into Q2 2027

Vivani Medical (VANI) has reported a net loss of $6.4 million for Q2 2026 and $13.2 million for the first half of 2026, with cash and equivalents totaling $19.9 million, which is projected to fund operations into Q2 2027. The company is advancing its …

Form 8K Vivani Medical Inc For: 13 August By Investing.com

This article reports on the filing of a Form 8K by Vivani Medical Inc. on August 13th, as tracked by Investing.com. The brief mention indicates a financial disclosure event for the company, with the stock symbol VANI noted to have experienced a -2.19% change.

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

Vivani Medical reported its second-quarter 2026 financial results, highlighting significant progress in its clinical development, including the successful dosing of all participants in its SLIM-1 Phase 1 trial for NPM-139, a semaglutide implant for chronic weight management. The company also announced a non-exclusive agreement …

20 Participants Dosed in Semaglutide Trial; Data Due in November

Vivani Medical (VANI) reported its Q2 2026 financial results, highlighting the successful dosing of all 20 participants in its Phase 1 SLIM-1™ trial for NPM-139, a semaglutide implant, with top-line data expected in November 2026. The company also announced a non-exclusive agreement with Novo …

Israel (TASE:ILCO) Stock Advances As Margin Squeeze Clouds Earnings Quality

Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Invivyd, Inc. announced its Q2 2026 financial results, reporting $14.3 million in PEMGARDA net product revenue, a 21% increase year-over-year. The company completed enrollment for its VYD2311 DECLARATION pivotal clinical trial and LIBERTY clinical trial, with top-line data for both anticipated in late Q3 …

Bank Leumi (TASE:LUMI) Stock Faces Margin Pressure Despite Strong Profitability

Vivakor and M2i Global Announce Strategic Collaboration to Advance U.S. Critical Minerals Supply Chain

Vivakor, Inc. and M2i Global, Inc. have entered into an Indication of Interest to explore a potential business combination. The collaboration aims to strengthen the U.S. critical minerals supply chain and advance domestic mineral independence. This strategic move could expand Vivakor's commodities marketing and …

M2i Global and Vivakor sign deal to explore merger to boost US critical minerals supply chain

M2i Global Inc and Vivakor Inc have signed a non-binding agreement to explore a merger. The proposed deal aims to combine M2i's critical minerals platform with Vivakor's commodities marketing and remediation businesses to create a larger US-focused platform. This merger is intended to strengthen …

El Al Israel Airlines (TASE:ELAL) Posted Strong Q2 Results, Is The Stock Still Undervalued?

Vivakor and M2i Set 30-Day Window to Explore Critical Minerals Deal

Vivakor (Nasdaq: VIVK) and M2i Global (OTCQB: MTWO) have signed an Indication of Interest (IOI) to explore a potential business combination and strategic collaboration focused on advancing the U.S. critical minerals supply chain. The IOI outlines an initial 30-day period for negotiating valuation, transaction …

EXCLUSIVE: Vivakor Targets Critical Minerals Expansion Through Potential M2i Acquisition

Vivakor Inc. (NASDAQ: VIVK) and M2i Global Inc. (OTCQB: MTWO) have signed a non-binding indication of interest to explore a potential business combination. This proposed merger aims to expand Vivakor's operations into critical minerals, support the U.S. critical minerals supply chain, and combine their …

Aviva (LSE:AV.) Tests Whether link between diversified insurance earnings and shareholder distributions Can Endure

Vivos Therapeutics Inc (VVOS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Israel (TASE:ILCO) Reports Stronger Earnings, Is The Valuation Discount Justified?

VivoSim: Fiscal Q1 Earnings Snapshot

VivoSim Labs, Inc. (VIVS) reported a fiscal first-quarter loss of $1.3 million, or 25 cents per share. The San Diego-based development-stage company, which focuses on functional human tissue for research, posted revenue of $18,000 for the period.

Telefonica Brasil (NYSE:VIV) Reaches New 1-Year Low - Here's Why

Telefonica Brasil (NYSE:VIV) shares hit a new 52-week low of $11.48, trading below its 50-day and 200-day moving averages. This drop follows weakened analyst sentiment, with several downgrades leading to a consensus "Reduce" rating and an average price target of $14.26. The company also …

HC Wainwright Issues Positive Forecast for Innoviva Earnings

Bitcore Capital Group Ltd Earnings and Revenue – TASE:BITC

VivoSim Labs Ord Shs (VIVS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for VivoSim Labs Ord Shs (VIVS), detailing its current stock performance, market capitalization, and P/E ratio. It also lists peer comparisons with other biotechnology and medical research companies, indicating the number of ratings and analysts for each. The …

Viva Energy (ASX:VEA) Tests Refining Upswing After Margin Surge

Three Innoviva therapies named finalists for Prix Galien award

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., announced that three of its infectious disease therapies—XACDURO, ZEVTERA, and NUZOLVENCE—have been named finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This marks the third consecutive year an Innoviva product …

Form 8K Vivos Therapeutics Inc For: 11 August By Investing.com

This article reports that Vivos Therapeutics Inc filed a Form 8K on August 11. It's a brief financial news item from Investing.com, noting the filing for the company with the stock symbol VVOS.

Vivos Therapeutics Strengthens IP for Sleep Apnea Devices

Vivakor reports increased crude oil marketing activity By Investing.com

Vivakor Inc. (NASDAQ:VIVK) has reported increased activity in its physical crude oil marketing platform due to geopolitical uncertainties in the Middle East causing volatility in global crude oil markets. The company's Vivakor Supply & Trading, LLC unit is experiencing higher activity and aims to …

Vivakor Sees Increased Activity as Oil Pricing Jumps Due to Continuing Middle East Conflict and Rising Uncertainty in Strait of Hormuz

Vivakor, Inc. (Nasdaq: VIVK) has reported increased activity in its Supply and Trading business, VST, driven by geopolitical instability in the Middle East and rising oil prices. The company attributes this growth to its strategic expansion, recurring contracted volumes, and expanding commercial relationships. Vivakor …

Vivid Seats (SEAT) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 8:30 a.m. ET CALL PARTICIPANTS General Counsel - Austin Arnett Chief Executive Officer - Larry Fey Chief Financial Officer - Joe Thomas Full Conference Call Transcript Operator: Good morning, and welcome to Vivid …

Vivos Oral Appliance Shows Improvement in Insomnia Severity

A single-site clinical study found that Vivos Therapeutics Inc's Vida oral appliance significantly improved insomnia severity in 100% of its 37 adult participants, reducing Insomnia Severity Index scores by an average of 65%. All patients saw at least one classification level improvement, with many …

Streeterville group discloses 9.25% stake in Vivos Therapeutics (VVOS)

Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife have jointly disclosed a 9.25% beneficial ownership stake in Vivos Therapeutics, Inc. (VVOS), totaling 1,812,031 shares. This filing, a Schedule 13G, indicates they hold sole voting and dispositive power over these shares, based on …

Vivakor (Nasdaq:VIVK) - Stock Analysis

This Simply Wall St stock analysis provides an overview of Vivakor (VIVK), a company involved in crude oil transportation, terminaling, and marketing. It highlights the company's low valuation, poor past performance, and high share price volatility, alongside a significant decline in earnings and shareholder …

Vivos Therapeutics Expands Greenway Health Partnership to Deploy AI-Enabled Platform Across All Clinical and Revenue Operations

Vivos Therapeutics is expanding its partnership with Greenway Health to implement the AI-by-design Novare platform across its clinical and revenue operations, starting with Sleep Centers of Nevada. This collaboration aims to generate significant annual value through increased patient capacity, improved revenue cycles, and substantial …

Vivos AI rollout could recover an estimated 46,000+ work hours in Nevada

Vivos Therapeutics is expanding its partnership with Greenway Health to deploy the AI-by-design Novare platform across its clinical and revenue operations, starting with Sleep Centers of Nevada (SCN). This initiative is estimated to generate about $9.1 million in annual value for Vivos at SCN, …

Vivos Therapeutics Expands AI Workflow Partnership with Greenway Health, Citing Up to $9.1 Million in Annual Value at Sleep Centers of Nevada

Vivos Therapeutics has partnered with Greenway Health to integrate its AI-powered Novare platform into Vivos' Sleep Centers of Nevada, projecting up to $9.1 million in annual value from increased patient capacity and revenue cycle improvements. This AI implementation is expected to save Vivos $1.8 …